Proposed Collection; Comment Request for Regulation Project, 15043-15044 [2019-07230]
Download as PDF
<![CDATA[
15043
Federal Register / Vol. 84, No. 71 / Friday, April 12, 2019 / Notices
NON-PROBABILITY SAMPLE
Number of
respondents
Category of respondent/activity
Participation
time
(minutes)
Burden hours
Read Invitation Email ...................................................................................................................
Read Reminder Email * ...............................................................................................................
Complete Survey .........................................................................................................................
461,540
431,540
60,000
0.5
0.25
** 5.5
3,846
1,798
5,500
Total Burden Hours ..............................................................................................................
........................
........................
11,144
* The estimate for the Reminder emails is based on the assumption that 50% of the needed respondents will complete the survey online in
time to not receive the Reminder email.
** Participant time is based on mean completion time for non-probability panel members during pilot survey fielding.
The following paragraph applies to all
of the collections of information covered
by this notice:
An agency may not conduct or
sponsor, and a person is not required to
respond to, a collection of information
unless the collection of information
displays a valid OMB control number.
Books or records relating to a collection
of information must be retained as long
as their contents may become material
in the administration of any internal
revenue law. Generally, tax returns and
tax return information are confidential,
as required by 26 U.S.C. 6103.
Request for Comments: Comments
submitted in response to this notice will
be summarized and/or included in the
request for OMB approval. Comments
will be of public record. Comments are
invited on: (a) Whether the collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information has practical utility; (b) the
accuracy of the agency’s estimate of the
burden of the collection of information;
(c) ways to enhance the quality, utility,
and clarity of the information to be
collected; (d) ways to minimize the
burden of the collection of information
on or other forms of information
technology; and (e) estimates of capital
or start-up costs and costs of operation,
maintenance, and purchase of services
to provide information.
Approved: April 8, 2019.
Laurie Brimmer,
Senior Tax Analyst.
[FR Doc. 2019–07228 Filed 4–11–19; 8:45 am]
BILLING CODE 4830–01–P
jbell on DSK30RV082PROD with NOTICES
DEPARTMENT OF THE TREASURY
Internal Revenue Service
Proposed Collection; Comment
Request for Regulation Project
Internal Revenue Service (IRS),
Treasury.
AGENCY:
VerDate Sep<11>2014
18:18 Apr 11, 2019
Jkt 247001
Notice and request for
comments.
ACTION:
The Internal Revenue Service,
as part of its continuing effort to reduce
paperwork and respondent burden,
invites the general public and other
Federal agencies to take this
opportunity to comment on continuing
information collections, as required by
the Paperwork Reduction Act of 1995.
The IRS is soliciting comments
concerning annual registration
statement identifying separated
participants with deferred vested
benefits.
SUMMARY:
Written comments should be
received on or before June 11, 2019 to
be assured of consideration.
ADDRESSES: Direct all written comments
to Laurie Brimmer, Internal Revenue
Service, Room 6529, 1111 Constitution
Avenue NW, Washington, DC 20224.
FOR FURTHER INFORMATION CONTACT:
Requests for additional information or
copies of the form should be directed to
Kerry Dennis, at (202) 317–5751 or
Internal Revenue Service, Room 6529,
1111 Constitution Avenue NW,
Washington DC 20224, or through the
internet, at Kerry.Dennis@irs.gov.
SUPPLEMENTARY INFORMATION:
Title: Annual Registration Statement
Identifying Separated Participants with
Deferred Vested Benefits.
OMB Number: 1545–2187.
Form Number: Form 8955–SSA.
Abstract: Form 8955–SSA, the
designated successor to Schedule SSA
(Form 5500), is used to satisfy the
reporting requirements of Internal
Revenue Code section 6057(a). Plan
administrators of employee benefit
plans subject to the vesting standards of
ERISA section 203 use the form to
report information about separated
participants with deferred vested
benefits under the plan. The
information is generally given to the
Social Security Administration (SSA),
which provides the reported
information to separated participants
DATES:
PO 00000
Frm 00133
Fmt 4703
Sfmt 4703
when they file for social security
benefits.
Current Actions: There is no change to
this form.
Type of Review: Extension of a
currently approved collection.
Affected Public: Businesses and other
for-profit organizations.
Estimated Number of Respondents:
200,000.
Estimated Time per Respondent: 50
minutes.
Estimated Total Annual Burden
Hours: 166,000.
The following paragraph applies to all
of the collections of information covered
by this notice.
An agency may not conduct or
sponsor, and a person is not required to
respond to, a collection of information
unless the collection of information
displays a valid OMB control number.
Books or records relating to a collection
of information must be retained as long
as their contents may become material
in the administration of any internal
revenue law. Generally, tax returns and
tax return information are confidential,
as required by 26 U.S.C. 6103.
Request for Comments: Comments
submitted in response to this notice will
be summarized and/or included in the
request for OMB approval. All
comments will become a matter of
public record. Comments are invited on:
(a) Whether the collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the collection of
information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; (d) ways to
minimize the burden of the collection of
information on respondents, including
through the use of automated collection
techniques or other forms of information
technology; and (e) estimates of capital
or start-up costs and costs of operation,
maintenance, and purchase of services
to provide information.
E:\FR\FM\12APN1.SGM
12APN1
15044
Federal Register / Vol. 84, No. 71 / Friday, April 12, 2019 / Notices
Approved: April 8, 2019.
Laurie Brimmer,
Senior Tax Analyst.
[FR Doc. 2019–07230 Filed 4–11–19; 8:45 am]
BILLING CODE 4830–01–P
DEPARTMENT OF VETERANS
AFFAIRS
Tiered Pharmacy Copayments for
Medications Update
Department of Veterans Affairs.
Notice.
AGENCY:
ACTION:
This Department of Veterans
Affairs (VA) Notice updates the
information on Tier 1 medications.
FOR FURTHER INFORMATION CONTACT:
Joseph Duran, Director of Policy and
Planning, Office of Community Care,
Veterans Health Administration,
Department of Veterans Affairs, 810
SUMMARY:
methodologies set forth in Section
17.110, this Notice updates the list of
Tier 1 medications.
Not less than once per year, VA will
identify a subset of multi-source
medications as Tier 1 medications. Only
medications that meet all of the criteria
in paragraphs (b)(2)(i), (ii), and (iii) of
Section 17.110 will be eligible to be
considered Tier 1 medications, and only
those medications that meet all of the
criteria in paragraph (b)(2)(i) of this
section will be assessed using the
criteria in paragraphs (b)(2)(ii) and (iii).
As of the date of this Notice, the Tier 1
medication list based on the
methodologies in Section 17.110 will be
posted on VA’s website (www.va.gov/
health) under the heading ‘‘Tier 1 Copay
Medication List.’’
The following table is the Tier 1
Copay Medication List that is effective
January 1, 2019, and will remain in
effect until December 31, 2019.
Condition
VA product name
Arthritis and Pain ................................................
Aspirin Buffered Tablet, Aspirin Chewable Tablet, Aspirin Enteric Coated Tablet, Allopurinol
Tablet, Ibuprofen Tablet, Meloxicam Tablet, Naproxen Tablet.
Clopidogrel Bisulfate Tablet, Warfarin Sodium Tablet.
Alendronate Tablet.
Atorvastatin Tablet, Gemfibrozil Tablet, Lovastatin Tablet, Niacin (Slo-Niacin) Tablet,
Pravastatin Tablet, Rosuvastatin Calcium Tablet, Simvastatin Tablet.
Donepezil Tablet, Memantine Hydrochloride (HCL) Tablet.
Glipizide Tablet, Metformin HCL Tablet, Metformin HCL 24-hour (HR) Sustained Action (SA)
Tablet, Pioglitazone HCL Tablet.
Potassium SA Tablet, Potassium SA Dispersible Tablet.
Omeprazole Enteric Coated (EC) Capsule, Pantoprazole Sodium EC Capsule, Ranitidine Tablet.
Brimonidine 0.2% Solution, Dorzolamide 2%/Timolol 0.5% Solution, Latanoprost 0.005% Solution, Timolol Maleate 0.25% Solution, Timolol Maleate 0.5% Solution.
Amlodipine Tablet, Amiodarone HCL Tablet, Aspirin (see Arthritis and Pain), Atenolol Tablet,
Carvedilol Tablet, Chlorthalidone Tablet, Clonidine Tablet, Diltiazem 24-Hour Capsule,
Diltiazem HCL Tablet, Enalapril Maleate Tablet, Furosemide Tablet, Hydrochlorothiazide
Capsule/Tablet, Hydrochlorothiazide/Lisinopril Tablet, Hydrochlorothiazide/Triamteren Capsule/Tablet, Isosorbide Mononitrate SA Tablet, Lisinopril Tablet, Losartan Tablet, Metoprolol
Succinate SA Tablet, Metoprolol Tartrate Tablet, Nifedipine SA Capsule, Nitroglycerin Sublingual Tablet, Prazosin HCL Capsule, Propranolol HCL Tablet, Spironolactone Tablet,
Valsartan Tablet, Verapamil HCL Tablet, Verapamil HCL SA Tablet.
Amitriptyline HCL Tablet, Bupropion HCL Tablet, Bupropion HCL SA (12–HR Sustained Release) Tablet, Bupropion HCL SA (24–HR Extended Release XL) Tablet, Buspirone HCL
Tablet, Citalopram Hydrobromide Tablet, Duloxetine HCL EC Capsule, Escitalopram Oxalate
Tablet, Fluoxetine Capsule/Tablet, Lithium Carbonate Capsule/Tablet, Mirtazapine Tablet,
Paroxetine HCL Tablet, Sertraline HCL Tablet, Trazodone Tablet, Venlafaxine HCL Tablet,
Venlafaxine HCL SA Tablet/Capsule.
Montelukast NA Tablet.
Gabapentin Capsule, Lamotrigine Tablet, Topiramate Tablet.
Levothyroxine Sodium Tablet.
Alfuzosin HCL SA Tablet, Doxazosin Mesylate Tablet, Finasteride Tablet, Oxybutynin Chloride
Tablet, Oxybutynin Chloride SA Tablet, Tamsulosin HCL Capsule, Terazosin HCL Capsule.
Blood Thinners and Platelet Inhibitors ...............
Bone Health ........................................................
Cholesterol ..........................................................
Dementia .............................................................
Diabetes ..............................................................
Electrolyte Supplement .......................................
Gastrointestinal Health .......................................
Glaucoma and Eye Care ....................................
Heart Health and Blood Pressure ......................
Mental Health ......................................................
Respiratory Condition .........................................
Seizures ..............................................................
Thyroid Conditions ..............................................
Urologic (Bladder and Prostate) Health .............
Signing Authority
jbell on DSK30RV082PROD with NOTICES
Vermont Avenue NW, Washington, DC
20420; email: Joseph.Duran2@va.gov;
telephone: (303) 372–4629 (this is not a
toll-free number).
SUPPLEMENTARY INFORMATION: Section
17.110 of Title 38 CFR governs
copayments for medications that VA
provides to Veterans. Section 17.110
provides the methodologies for
establishing the copayment amount for
each 30-day or less supply of
medication provided by VA on an
outpatient basis (other than medication
administered during treatment).
Section 17.110 provides a list of Tier
1 medications that will be published as
a Notice in the Federal Register and
will be posted on VA’s website
(www.va.gov/health) at least once per
year. Tier 1 medication means a multisource medication that has been
identified using the process described in
Section 17.110(b)(2). 38 CFR Section
17.110(b)(1)(iv)(B). Based on the
The Secretary of Veterans Affairs, or
designee, approved this document and
authorized the undersigned to sign and
submit the document to the Office of the
Federal Register for publication
electronically as an official document of
the Department of Veterans Affairs.
Robert L. Wilkie, Secretary, Department
VerDate Sep<11>2014
18:18 Apr 11, 2019
Jkt 247001
of Veterans Affairs, approved this
document on March 14, 2019, for
publication.
PO 00000
Dated: April 9, 2019.
Luvenia Potts,
Program Specialist, Office of Regulation
Policy & Management, Office of the Secretary,
Department of Veterans Affairs.
[FR Doc. 2019–07336 Filed 4–11–19; 8:45 am]
BILLING CODE 8320–01–P
Frm 00134
Fmt 4703
Sfmt 9990
E:\FR\FM\12APN1.SGM
12APN1
]]>Agencies
[Federal Register Volume 84, Number 71 (Friday, April 12, 2019)]
[Notices]
[Pages 15043-15044]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-07230]
-----------------------------------------------------------------------
DEPARTMENT OF THE TREASURY
Internal Revenue Service
Proposed Collection; Comment Request for Regulation Project
AGENCY: Internal Revenue Service (IRS), Treasury.
ACTION: Notice and request for comments.
-----------------------------------------------------------------------
SUMMARY: The Internal Revenue Service, as part of its continuing effort
to reduce paperwork and respondent burden, invites the general public
and other Federal agencies to take this opportunity to comment on
continuing information collections, as required by the Paperwork
Reduction Act of 1995. The IRS is soliciting comments concerning annual
registration statement identifying separated participants with deferred
vested benefits.
DATES: Written comments should be received on or before June 11, 2019
to be assured of consideration.
ADDRESSES: Direct all written comments to Laurie Brimmer, Internal
Revenue Service, Room 6529, 1111 Constitution Avenue NW, Washington, DC
20224.
FOR FURTHER INFORMATION CONTACT: Requests for additional information or
copies of the form should be directed to Kerry Dennis, at (202) 317-
5751 or Internal Revenue Service, Room 6529, 1111 Constitution Avenue
NW, Washington DC 20224, or through the internet, at
[email protected].
SUPPLEMENTARY INFORMATION:
Title: Annual Registration Statement Identifying Separated
Participants with Deferred Vested Benefits.
OMB Number: 1545-2187.
Form Number: Form 8955-SSA.
Abstract: Form 8955-SSA, the designated successor to Schedule SSA
(Form 5500), is used to satisfy the reporting requirements of Internal
Revenue Code section 6057(a). Plan administrators of employee benefit
plans subject to the vesting standards of ERISA section 203 use the
form to report information about separated participants with deferred
vested benefits under the plan. The information is generally given to
the Social Security Administration (SSA), which provides the reported
information to separated participants when they file for social
security benefits.
Current Actions: There is no change to this form.
Type of Review: Extension of a currently approved collection.
Affected Public: Businesses and other for-profit organizations.
Estimated Number of Respondents: 200,000.
Estimated Time per Respondent: 50 minutes.
Estimated Total Annual Burden Hours: 166,000.
The following paragraph applies to all of the collections of
information covered by this notice.
An agency may not conduct or sponsor, and a person is not required
to respond to, a collection of information unless the collection of
information displays a valid OMB control number. Books or records
relating to a collection of information must be retained as long as
their contents may become material in the administration of any
internal revenue law. Generally, tax returns and tax return information
are confidential, as required by 26 U.S.C. 6103.
Request for Comments: Comments submitted in response to this notice
will be summarized and/or included in the request for OMB approval. All
comments will become a matter of public record. Comments are invited
on: (a) Whether the collection of information is necessary for the
proper performance of the functions of the agency, including whether
the information shall have practical utility; (b) the accuracy of the
agency's estimate of the burden of the collection of information; (c)
ways to enhance the quality, utility, and clarity of the information to
be collected; (d) ways to minimize the burden of the collection of
information on respondents, including through the use of automated
collection techniques or other forms of information technology; and (e)
estimates of capital or start-up costs and costs of operation,
maintenance, and purchase of services to provide information.
[[Page 15044]]
Approved: April 8, 2019.
Laurie Brimmer,
Senior Tax Analyst.
[FR Doc. 2019-07230 Filed 4-11-19; 8:45 am]
BILLING CODE 4830-01-P
